Scan to Download ios&Android APP

Trade SAB Biotherapeutics, Inc. - SABS CFD

1.03
4.63%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.08
Open* 1.08
Day's Range* 1.03 - 1.03
1-Year Change* 2.86%
Volume N/A
Average Vol. (3m) 0.99175
52 wk Range N/A
Market Cap 47.7643
P/E Ratio N/A
Shares Outstanding 42962100
Revenue 72.6792
EPS -0.55775
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Nov 21, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 18, 2022 1.08 -0.03 -2.70% 1.11 1.16 1.05
Aug 17, 2022 1.08 -0.04 -3.57% 1.12 1.14 1.08
Aug 16, 2022 1.13 -0.02 -1.74% 1.15 1.15 1.06
Aug 15, 2022 1.15 0.03 2.68% 1.12 1.21 1.10
Aug 12, 2022 1.10 0.00 0.00% 1.10 1.11 1.07
Aug 11, 2022 1.08 -0.08 -6.90% 1.16 1.18 1.04
Aug 10, 2022 1.06 -0.07 -6.19% 1.13 1.13 1.04
Aug 9, 2022 1.13 -0.06 -5.04% 1.19 1.21 1.13
Aug 8, 2022 1.18 0.00 0.00% 1.18 1.21 1.15
Aug 5, 2022 1.15 -0.02 -1.71% 1.17 1.19 1.15
Aug 4, 2022 1.13 0.03 2.73% 1.10 1.22 1.10
Aug 3, 2022 1.12 0.02 1.82% 1.10 1.14 1.07
Aug 2, 2022 1.08 -0.02 -1.82% 1.10 1.11 1.01
Aug 1, 2022 1.06 -0.03 -2.75% 1.09 1.09 0.98
Jul 29, 2022 1.04 -0.06 -5.45% 1.10 1.15 1.04
Jul 28, 2022 1.10 -0.08 -6.78% 1.18 1.20 1.10
Jul 27, 2022 1.17 0.03 2.63% 1.14 1.20 1.11
Jul 26, 2022 1.16 -0.01 -0.85% 1.17 1.22 1.16
Jul 25, 2022 1.16 -0.03 -2.52% 1.19 1.21 1.16
Jul 22, 2022 1.21 0.00 0.00% 1.21 1.23 1.18

SAB Biotherapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2020 2021
Total revenue 55.2378 60.8761
Revenue 55.2378 60.8761
Total Operating Expense 34.681 73.6037
Selling/General/Admin. Expenses, Total 6.7723 17.0857
Research & Development 27.9087 57.1836
Unusual Expense (Income) 0 -0.6656
Operating Income 20.5568 -12.7276
Interest Income (Expense), Net Non-Operating -0.44302 -4.42241
Other, Net 0.004 0.00549
Net Income Before Taxes 20.1178 -17.1445
Net Income After Taxes 20.1178 -17.1445
Net Income Before Extra. Items 20.1178 -17.1445
Net Income 20.1178 -17.1445
Income Available to Common Excl. Extra. Items 20.1178 -17.1445
Income Available to Common Incl. Extra. Items 20.1178 -17.1445
Diluted Net Income 20.1178 -17.1445
Diluted Weighted Average Shares 27.0115 42.9551
Diluted EPS Excluding Extraordinary Items 0.74479 -0.39913
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS 0.74479 -0.41462
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 60.8761 11.8031
Total Operating Expense 0.11161 0.25685 0.33555 72.8997 18.5104
Other Operating Expenses, Total 0.11161 0.25685 0.33555 -0.70401
Operating Income -0.11161 -0.25685 -0.33555 -12.0236 -6.70734
Interest Income (Expense), Net Non-Operating 0.00242 0.0029 0.00293 -4.42241 7.78549
Other, Net 3.08241 -1.94821 0.00179 -1.13875
Net Income Before Taxes 2.97322 -2.20216 -0.33083 -17.5848 1.07814
Net Income After Taxes 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Net Income Before Extra. Items 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Net Income 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Income Available to Common Excl. Extra. Items 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Income Available to Common Incl. Extra. Items 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Diluted Net Income 2.97322 -2.20216 -0.33083 -17.5848 0.98586
Diluted Weighted Average Shares 3.53205 14.7922 14.7922 42.9551 43.1133
Diluted EPS Excluding Extraordinary Items 0.84178 -0.14887 -0.02237 -0.40938 0.02287
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.84178 -0.14887 -0.02237 -0.42487 0.02287
Revenue 60.8761 11.8031
Selling/General/Admin. Expenses, Total 17.0857 5.18607
Research & Development 57.1836 13.2113
Unusual Expense (Income) -0.6656 0
Depreciation / Amortization 0.041
Interest Expense (Income) - Net Operating 0.072
  • Annual
  • Quarterly
2020 2021
Total Current Assets 34.455 48.4202
Cash and Short Term Investments 12.6104 33.2067
Cash & Equivalents 12.6104 33.2067
Total Receivables, Net 20.5695 8.01071
Accounts Receivable - Trade, Net 20.5695 8.01071
Prepaid Expenses 1.27513 0.86451
Other Current Assets, Total 0 6.33831
Total Assets 56.5379 79.3692
Property/Plant/Equipment, Total - Net 22.0829 30.949
Property/Plant/Equipment, Total - Gross 23.8501 34.169
Accumulated Depreciation, Total -1.76719 -3.22002
Total Current Liabilities 11.0617 24.6836
Accounts Payable 7.38236 4.45853
Accrued Expenses 2.82914 13.382
Notes Payable/Short Term Debt 0 0
Current Port. of LT Debt/Capital Leases 0.73345 0.18606
Other Current Liabilities, Total 0.11678 6.65692
Total Liabilities 17.5301 40.8193
Total Long Term Debt 4.09559 3.76243
Long Term Debt 0.17204 0
Capital Lease Obligations 3.92355 3.76243
Other Liabilities, Total 2.37278 12.3733
Total Equity 39.0078 38.5499
Common Stock 0.0026 0.00435
Additional Paid-In Capital 50.9897 67.6745
Retained Earnings (Accumulated Deficit) -11.9844 -29.129
Total Liabilities & Shareholders’ Equity 56.5379 79.3692
Total Common Shares Outstanding 25.9734 43.4873
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 1.12064 0.93667 0.77062 48.4202 36.1697
Cash and Short Term Investments 0.85806 0.7568 0.66787 33.2067 22.4084
Cash 0.85806 0.7568 0.66787
Prepaid Expenses 0.26258 0.17987 0.10274 0.86451 1.97491
Total Assets 117.273 117.092 116.929 79.3692 67.4725
Long Term Investments 116.152 116.155 116.158
Other Long Term Assets, Total 0
Total Current Liabilities 0.08 0.15288 0.32238 24.6836 18.2559
Accrued Expenses 0.08 0.15288 0.32238 13.5983 12.9613
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 7.8834 9.90449 10.0722 40.8193 26.2142
Total Long Term Debt 0 0 0 3.76243 3.72894
Other Liabilities, Total 7.8034 9.75161 9.74981 12.3733 4.22939
Total Equity 109.39 107.188 106.857 38.5499 41.2583
Common Stock 104.39 102.188 116.15 0.00435 0.00435
Additional Paid-In Capital 2.03534 4.23747 0 67.6745 74.9183
Retained Earnings (Accumulated Deficit) 2.96422 0.76206 -9.29366 -29.129 -28.1431
Total Liabilities & Shareholders’ Equity 117.273 117.092 116.929 79.3692 67.4725
Total Common Shares Outstanding 14.7922 14.7922 14.7922 43.4873 42.9551
Cash & Equivalents 33.2067 22.4084
Total Receivables, Net 8.01071 11.7864
Accounts Receivable - Trade, Net 8.01071 11.7864
Other Current Assets, Total 6.33831 0
Property/Plant/Equipment, Total - Net 30.949 31.3027
Accounts Payable 4.45853 4.98139
Current Port. of LT Debt/Capital Leases 0.18606 0.17091
Other Current Liabilities, Total 6.44067 0.14228
Long Term Debt 0
Capital Lease Obligations 3.76243 3.72894
Property/Plant/Equipment, Total - Gross 35.0665
Accumulated Depreciation, Total -3.76377
Treasury Stock - Common -5.52125
  • Annual
  • Quarterly
2020 2021
Net income/Starting Line 20.1178 -17.1445
Cash From Operating Activities 10.0048 3.75858
Cash From Operating Activities 0.38314 1.48861
Non-Cash Items 1.45821 5.95965
Changes in Working Capital -11.9543 13.4549
Cash From Investing Activities -12.7227 -10.9437
Capital Expenditures -12.7317 -10.9437
Other Investing Cash Flow Items, Total 0.009 0
Cash From Financing Activities 8.98232 34.1197
Issuance (Retirement) of Stock, Net 10.5618 34.347
Issuance (Retirement) of Debt, Net -1.5795 -0.22727
Net Change in Cash 6.26441 26.9346
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 2.97322 0.77106 0.44023 -17.1445 0.98586
Cash From Operating Activities -0.36316 -0.46441 -0.55334 3.75858 -10.2935
Non-Cash Items -3.08483 -1.13952 -1.14424 5.95965 -6.92504
Changes in Working Capital -0.25155 -0.09595 0.15067 13.4549 -5.08284
Cash From Investing Activities -116.15 -116.15 -116.15 -10.9437 -1.28093
Other Investing Cash Flow Items, Total -116.15 -116.15 -116.15 0 0.07639
Cash From Financing Activities 117.286 117.286 117.286 34.1197 -5.56217
Financing Cash Flow Items -0.20823 -0.20823 -0.20823
Issuance (Retirement) of Stock, Net 117.645 117.645 117.645 34.347 -5.51342
Issuance (Retirement) of Debt, Net -0.15 -0.15 -0.15 -0.22727 -0.04875
Net Change in Cash 0.77322 0.67197 0.58304 26.9346 -17.1366
Cash From Operating Activities 1.48861 0.63624
Capital Expenditures -10.9437 -1.35732
Deferred Taxes 0.09228

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

SAB Biotherapeutics, Inc. Company profile

About SAB Biotherapeutics Inc

SAB Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.

Financial summary

BRIEF: For the nine months ended 30 September 2021, SAB Biotherapeutics Inc revenues was not reported. Net income totaled to $440K.

Industry: Biotechnology & Medical Research (NEC)

2100 East 54Th Street North
Suite 202
SIOUX FALLS
SOUTH DAKOTA 57104
US

Income statement

People Also Watch

US Tech 100 (Nasdaq)

13,244.70 Price
-2.040% 1D Chg, %
Long position overnight fee -0.0118%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 1.5

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading